Microbot Medical Inc. (Nasdaq: MBOT) announced on November 16, 2026, that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2026. The filing, submitted via an 8-K current report, highlights a decrease in revenue compared to the previous quarter alongside continued expansion of the LIBERTY Endovascular Robotic System.
The company reported revenue of $72,000 for the third quarter of 2026. This figure represents a sequential decrease from the $241,000 reported in the second quarter of 2026. The filing attributes this decline to timing issues regarding customer re-orders and the seasonality of the summer months.
Despite the revenue drop, the company noted that 100% of current customers who exhausted their initial inventory have reordered multiple systems. Additionally, the utilization of the LIBERTY System increased by 44% during the third quarter compared to the second quarter.
Financial metrics for the quarter included a negative gross margin. Cost of goods sold increased by 24% from the second quarter, largely due to an inventory write-down and the use of the first-in, first-out (FIFO) inventory method, which sold units manufactured at higher production costs. However, the company stated that the manufacturing cost per unit for systems produced in the third quarter continued to decline.
Microbot Medical reported cash, cash equivalents, and marketable securities of approximately $62 million as of the end of the third quarter. The company also disclosed that it entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market the LIBERTY System in Israel, with initial orders expected in the fourth quarter of 2026.
As of the report date, the company held 44 issued patents and 49 pending patent applications. The company also successfully completed an ISO certificate surveillance audit.